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Abstract
Background: Human T-cell leukemia virus (HTLV-1) is a lymphotropic retrovirus associated to adult T cell leukemia
(ATL) and to non-neoplastic inflammatory conditions affecting the central nervous system, lung or skin. The
inflammatory disorders associated to HTLV-1 are mediated by different proinflammatory cytokines as IL-1α, IL-6,
TNF-α. The release and the role of IL-17 is still debated. Aims of this study were to analyze IL-17 induction by
HTLV-1 infection and to determine whether resveratrol (RES) is able to down regulate the pathway of cytokines
production either in HTLV-1 chronically infected MT-2 cell line or in human CD4+ cells infected in vitro with HTLV-1.
Methods: MT-2 and HTLV-1 infected CD4+ cells were analyzed for proinflammatory cytokine production before or
after RES treatment. The concentrations of IL-17, IL-1α, IL-6, and TNF-α were measured in cell culture supernatants by
ELISA and SearchLight™ technology. The IL-17 mRNA expression was evaluated by RT-PCR. NF-kB activation was
detected by non-radioactive, Electro Mobility Shift Assay (EMSA). HTLV-1 RNA expression was detected by Real-
time-PCR (RQ-PCR).
Results: We found that RES is capable of inducing a dose-dependent inhibition of IL-1α, IL-6 and TNF-α production in
vitro and can down regulate the expression of IL-17 at both mRNA and protein levels in HTLV-1 infected cells. This
effect was associated with a dose-dependent inhibition of the of the nuclear factor kappa-B (NF-kB) activity. Conversely,
RES did not apparently affect HTLV-1 proliferation.
Conclusions: These results support the anti-inflammatory properties of RES, suggesting that it might be a useful
therapeutic agent for the treatment of HTLV-1 related inflammatory diseases.
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Background
The HTLV-1 virus infects approximately 10–20 million
people worldwide [1]. Firstly identified as the etiological
agent of ATL it was successively associated with progres-
sive neurological disorders such as the HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), a
chronic inflammatory disease of the central nervous sys-
tem [2]. Other non-neoplastic inflammatory diseases such
as uveitis, Sjögren syndrome,arthritis polymyositis and
periodontitis, have been also recently associated to HTLV-
1 infection [3].
The HTLV-1 associated disorders HAM/TSP is char-
acterized by spontaneous proliferation of CD4+ lympho-
cytes that harbor a provirus, which appear capable of
promoting an active expansion of infected T cells. In-
flammatory cytokines have been involved in the patho-
genesis of HAM/TSP and high levels of IL-2, IFN-γ, and
TNF-α appear to contribute to neurological damage in
HAM/TSP patients [4]. HTLV-1 is capable to infect
CD4+ T and CD8+ T cells in vitro [5] and to
immortalize healthy CD4+ T cells that undergo to an ac-
tive expansion and proliferation [6]. Although HTLV-1-
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associated disorders have been extensively studied, the
mechanism by which HTLV-1 induces inflammatory
conditions is still unclear. Moreover, the exact cellular
and molecular events underlying the induction of
chronic inflammation during infection is not completely
understood.
The HTLV-1 provirus encodes a trans-acting factor
(Tax) that operates in association with the activating
transcription factor/CRE binding protein (ATF/CREB) to
enhance virus transcription. Tax induces the expression
of both viral and several cellular genes involved in differ-
ent pathways [7]. Interestingly, HTLV-1 Tax has potent
effects on infected T cells, including activation of nuclear
factor NF-kB with a subsequent enhancement of cell
proliferation and expression of different genes [8]. Per-
ipheral blood mononuclear cells (PBMC) naturally
infected by HTLV-1, such as in HAM/TSP disease, preco-
ciously express intracellular Tax protein and interferon-γ
(IFN-γ) in mitogen- stimulated short term culture, while
the expression of IL-2 and TNF-α requires longer culture
time [9, 10]. In agreement with these experimental data, a
recent study showed that an increase of IFN-γ and TNF-α
is involved in the tissue damage observed in clinical com-
plications of HTLV-1 infection [11]. In HTLV-1-infected
T cells, Tax up-regulates the expression of IL-17 and of its
mRNA [12] and lymphocytes from a HAM/TSP patient
have been shown to express in vitro detectable levels of
Tax and IL-17 mRNA [13]. Thus, clinical and experimen-
tal data suggest that HTLV-I infected cells are prone to
produce inflammatory cytokines which might in turn acti-
vate resident immune cells and amplify production of pro-
inflammatory mediators within tissues in HTLV-1 infected
patients. In light of this, individuals considered at risk of
HTLV-1 related chronic inflammation could be optimal
candidates to be treated with immunomodulatory agents
as an adjuvant therapy.
Resveratrol (RES), or trans-3,5,4’-trihydroxystibene, is
a polyphenolic, antifungal natural phytoalexin found in
grapevines (Vitis vinifera) and a variety of other plants.
RES has been shown to possess potent antioxidant and
anticancer properties and has been investigated for its
immunomodulating and anti-inflammatory capabilities
[14–16]. In our previous studies [17] we have demon-
strated that RES is able to modulate the expression of
cytokines in CD4+ and CD8+ T cells stimulated with
anti-CD3/anti-CD28, and could produce an inhibitory
effect on IFN − γ, IL-2 and IL-4 production when used
at high concentration. We have previously described
[18] a significant inhibitory effects of RES, as well as of
its derivative polydatin product, on the production of
IL-17 in a model of cell inflammation in vitro. In
addition, recent studies have reported that RES is ac-
tive in a wide variety of virus infection [19, 20] re-
vealing strong antiviral activity and an inhibitory
effect on proinflammatory cytokine secretion in en-
terovirus 71 (EV71) infected cells [21].
The capability of RES in blocking nuclear factor
kappa-B (NF-kB) mediated catabolic activity [14] makes
him a promising therapeutic agent for the treatment of
inflammatory conditions suggesting its potential clinical
relevance in the therapy of inflammatory diseases.
This study was aimed at evaluating the in vitro effect
of RES on the production of proinflammatory cytokines,
including IL-17, in a HTLV-1 chronically infected cell
line (MT-2), and in HTLV-1 infected immortalized hu-
man CD4+ T lymphocytes.
Methods
Reagents
Natural RES was extracted and kindly supplied by Dr.
Fulvio Mattivi, (Fondazione Edmund Mach, IASMA)
Italy. The purity of the compound tested by HPLC-MS,
UV, and NMR was higher than 99 % (method patented,
Ravagnan et al. 2001, PCT/IB01/00983) [22]. RES was
dissolved in dimethyl sulfoxide (DMSO, Sigma Chemical
Co., St. Louis, USA) at 100 mM stock solution. The
stock solutions were stored at −80 °C and diluted in cul-
ture medium just prior to use.
Cells
MT-2 cells, a HTLV-1 producing cell line derived from
cord blood lymphocytes infected in vitro with HTLV-1
from infected patients [23], were grown in RPMI-1640
with 20 % heat-inactivated fetal calf serum (FCS-
Hyclone Laboratories, Logan, UK), (Hyclone Europe,
Cramlington, UK) 2 mM L-glutamine and penicillin-
streptomycin (Life Technologies Ltd., Paisley, Scotland),
hereafter referred to as complete medium (CM) and split
weekly.
To assess HTLV-1 infection in vitro, lymphocytes were
isolated from peripheral blood mononuclear cells (PBMC),
obtained from healthy donors. Buffy coats were purified
by Ficoll-hypaque gradient centrifugation (Sigma-Aldrich
Corp) and CD4+/CD3+ cells were isolated by separation
through immunomagnetic beads [6]. HTLV-1 infection
was obtained by co-cultivating CD4+ lymphocytes with le-
thally irradiated (120 Gy, from a cesium Gamma cell
1000, Atomic Energy Canada) HTLV-I producing MT-2
cells at an acceptor: donor ratio of 3:1. Co-cultures were
maintained in the presence of recombinant IL-2 (rIL-2,
Hoffman-la Roche, Basel Switzerland) and split weekly
The presence of HTLV-1 proviral DNA and of Tax/Rex
mRNA in infected cells was determined at several time
during the culture.
Cell growth and total number of viable cells were
determined by the MTT assay and by the Trypan blue
dye exclusion test, respectively, according to standard
procedures.
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Cytokine production and analysis
MT-2 and HTLV-1 infected CD4+ cells were harvested,
counted, suspended in CM and seeded into 24-well tis-
sue culture plates (Falcon) in 1 ml/well at a concentra-
tion of 1x105 cell/ ml. The plates were incubated at 37 °
C in a 5 % CO2 humidified atmosphere for 30 min, 1, 3,
6, 12, 24, 48 or 72 h. Each culture was set in triplicate.
At each time, cells were analyzed for proinflammatory
cytokine production. Culture supernatants of MT-2 and
HTLV-1 infected CD4 + cells were collected as control
for cytokine detection.
The concentrations of IL-1α, IL-6, and TNF-α were
measured in undiluted cell culture supernatants in tripli-
cate by multiplex enzyme-linked immunosorbent assay
based on SearchLight™ technology (Thermo Fisher Sci-
entific Pierce Searchlight Products, Woburn, MA). The
amount of signal produced is proportional to the
amount of each protein in the sample detected with a
cooled CCD camera. The assay [24] is capable of detect-
ing target proteins at pg/ml concentrations.
To detect IL-17 production, a quantitative sandwich
enzyme immunoassay (R&D Systems). technique specific
for natural and recombinant human protein was used.
According to the manufacturer, the detection limit of
the assays was approximately 15.0 pg/ml.
RES treatment
MT-2 and HTLV-1 infected CD4+ cells were harvested,
counted, suspended in CM and seeded into 24-well tis-
sue culture plates (Falcon) in 1 ml/well volume at a con-
centration of 1x105 cell/ml. Cells were incubated in the
presence or in the absence of RES at final concentrations
of 0.625, 1.2, 2.5, 5, 10, 20, 40 μg/ml, or with DMSO
alone as control. The plates were incubated for 0.5-48 h
at 37 °C in a 5 % CO2. After each treatment, cell growth
and viable cells were determined by Trypan blue exclu-
sion test(data not shown). To evaluate the duration of
the inhibitory effect of resveratrol on IL-17 production,
MT-2 cells (2.5 104 cell/ml) were treated with 20–40 μg/
ml RES for 48 h and then washed and re-seeded into 24-
well tissue culture plates at a concentration of 1x105
cell/ ml. Culture supernatants were collected for IL-17
detection (ELISA kit Quantikine, h-IL-17 immunoassay,
R&D Systems, Minneapolis, USA).
IL-17 mRNA expression through RT-PCR
Total RNA was extracted from MT-2 and HTLV-1 in-
fected cells using the RNeasy mini kit (Qiagen), accord-
ing to manufacturer’s instructions. RNA was extracted
from either non-treated cells or from cells treated with
20 μg/ml of RES. Reverse transcription-PCR was carried
out with the PCR CORE kit (Applied Biosystem, Roche)
using random hexamers and 1 μg total RNA for first-
strand synthesis. The cDNA encoding IL-17 was amplified
using the oligonucleotides IL-17 forward (5’-ATGACT
CCTGGGAAGACCTCATTG-3’) and IL-17 reverse (5’-
CTTAGGCCACATGGTGGACAATCG −3’) by 40 PCR
cycles of 95° for 30 s, 70° for 30 s, and 72° for 30 s. As
control, the constitutive human GAPDH cDNA was
PCR amplified using the oligonucleotides GAPDH for-
ward (5’-ATGGTTTACATGTTCCAATATGATTCC-3’)
and GAPDH reverse (5’-CTTACTCCTTGGAGGCCA
TGTGGG-3’). The amplified products were electropho-
resed on 2 % agarose gel in 1× TAE (Tris acetate EDTA).
Detection of HTLV-1 RNA expression by Real-time-PCR
(RQ-PCR)
RNA isolation was performed using EuroGOLD total
RNA kit (Euroclone), according to the manufacturer’s
instructions. For RQ-PCR, 250 ng of total RNA from
each sample was reverse transcribed in a total volume of
20 μl using the high-capacity cDNA reverse transcrip-
tion kit (Applied Biosystems, CA, USA), according to
the manufacturer’s instructions. Amplification of specific
PCR products was detected using the iQ SYBR Green
Supermix (Bio-Rad, CA, USA). The RQ-PCR was per-
formed in triplicate in a total reaction volume of 25 μl
containing 1X Sybr green RQ-PCR Mix, 150 nM forward
and reverse primers, and 200 ng cDNA as a template.
Samples were heated for 10 min at 95 °C and were sub-
jected to 40 cycles of PCR amplification, each cycle con-
sisting of 15 s at 95 °C and 60 s at 60 °C. For the
detection of the HTLV-1 Tax/Rex region expression,
RPXPR1 and RPX4 primers were used (Kinoshita and
others 1989). Within each experiment, no-template con-
trol was used to verify any contamination, and the glucu-
ronidase beta (GUSB) housekeeping gene (NM_000181;
forward primer, 5’-CAGTTCCCTCCAGCTTCAATG-3’,
and reverse primer, 5’-ACCCAGCCGACAAAATGC-3’)
used as a reference gene, was run in parallel. Each run was
completed with a melting curve analysis to confirm the
specificity of amplification and lack of unspecific products
and primer dimers. Quantification was performed using
the Ct comparative method. Relative gene mRNA levels
were calculated as follows: 2 - [ΔCt (sample) - ΔCt (cali-
brator)] = 2 - ΔΔCt, where ΔCt (sample) = [Ct(tax/gag
gene) −Ct (GUSB)] represents the difference, in threshold
cycle number, between genes and GUSB. RQ-PCR experi-
ments were run on RT CFX96 Real-Time PCR Detection
System (Bio-Rad). All primers were purchased from
Primm (Milano Italy).
NF-kB binding assay
NF-kB activation was detected by non-radioactive, Elec-
tro Mobility Shift Assay (EMSA), as previously described
(Matteucci and others 2010). Briefly, aliquots of 10 μg of
nuclear extracts from 5x106 MT-2 cells, exposed or not
to different concentrations of RES and prepared as
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previously described (Matteucci and others 2010), were
incubated with 6 pmoles of biotin-labelled oligonucleo-
tide probe containing the specific recognition sequence
for NF-kB (AGTTGAGGGGACTTTCCCAGGC) and
poly-dI-dC, to prevent unspecific reaction, in binding
buffer. Binding reactions were incubated for 20 min at
room temperature. The protein-DNA complexes were
resolved on a 5 % native polyacrylamide gel in TBE buf-
fer and then transferred to “Zeta-probe GT Genomic”
blotting membranes (Bio-Rad). Signal from biotin-
labelled probe was detected using reagents provided in
the “LightShift chemiluminescent EMSA module”
(Pierce, Rockford, IL) followed by exposure to autoradi-
ography film. The NIH ImageJ software (version 1.46r,
Bethesda, MD, USA) was used to evaluate densitometry
of scanned films from EMSA. The integrated density of
all the pixels in the area of each signal was quantified
and adjusted by a background subtraction of density in
an adjacent blank area of the same size. This value rep-
resents the optical density of each shift in the films.
Relative density was calculated as the ratio between
RES-treated and vehicle-treated samples.
Statistics
All tests were run in triplicate or quadruplicate for each
experimental condition and each experiment were re-
peated at least 3 times. Data were analyzed by a 1-way
ANOVA with a post hoc Tukey’s test.
Results
Monitoring of cytokines production in MT-2 and HTLV-1
infected CD4 + lymphocytes
In order to evaluate the production of cytokines induced
by an HTLV-1 infection we analyzed the kinetics of IL-
17, IL-1α, IL-6 and TNF-α production in the cell culture
supernatants of MT-2 cells and of peripheral T CD4+
cells infected in vitro with HTLV-1. These determina-
tions were performed by ELISA at different time points:
after 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h and 72 h of
culture. Each time point was tested on quadruplicate
samples and expressed as pg/ml of culture supernatant.
The concentrations of IL-1α, IL-6,TNF-α and IL-17,
detected in the supernatants of MT-2 cells and HTLV-1
infected CD4 + cells are described in Table 1. Data
showed that all the cytokines reached higher levels in
HTLV-1 infected CD4+ cells than in MT-2 cells. Al-
though IL-17 was found in both cell cultures, with a
peak around 24–48 h, it was detectable earlier in MT-2
than in HTLV-1 infected CD4 + lymphocytes. Differently
from what observed for IL-17 release, IL-1α, IL-6 and
TNF-α level were detectable earlier in lymphocytes than
in MT-2 cell supernatants. In particular, initial amounts
of both TNF-α and IL-1α in MT-2 cell were very low
and reached levels comparable to those detected in
HTLV-1 infected CD4+ cells supernatants after 24–48 h
of culture.
In the case of HTLV-1 infected CD4 cell line, the ex-
pression of the virus was relatively stable during the on-
going of the culture and, consequently, could not affect
by itself the cytokine production.
Effect of RES on proinflammatory cytokines production
The inhibitory effects of RES on IL-1-α, IL-6 and TNF-α
release in MT-2 cells, after treatment with 20 μg/ml and
40 μg/ml of RES for 1 h, 24 h and 48 h in comparison
with untreated cells, are shown in Fig. 1. According to
the length of treatment: a) no inhibition after 1 h; b) sig-
nificant, dose dependent reduction of IL-6 and TNF-α
(100 %) after 24 h, at both concentrations (P < 0.01); c)
significant reduction of IL-1α and TNF-α production, at
both concentrations (P < 0.01), and recovery of IL-6 pro-
duction, after 48 h. The inhibitory effect on TNF-α was
visible also at the lowest concentrations of RES (from
0.612 to 2.5 μg/ml) and lasted until 48 h (data not
shown).
Levels of IL-17 were evaluated in culture supernatants
from MT-2 cells and HTLV-1 infected CD4+ cells after
48 h of addition of RES at different concentrations
(0.612, 1.25, 2.5, 5, 10, 20 and 40 μg/ml), cultures with
DMSO alone were prepared as negative controls. Re-
sults, expressed in terms of IC50 inhibitory dose, i.e. the
concentration of RES reducing 50 % of IL-17 produc-
tion, are illustrated in Fig. 2 Panel a. RES induced a
dose-dependent inhibition on IL-17 production, reach-
ing 100 % of inhibition at 20 μg/ml in HTLV-1 infected
Table 1 Proinflammatory cytokines production by MT-2 (A) and
HTLV-1 infected CD4+ cells (B)
A
Times IL-1 α (pg/ml)a IL- 6 (pg/ml)a TNF-α (pg/ml)a IL-17 (pg/ml)a
30 m 2.7 ± 0,35 29 ± 2.97 0 27.1 ± 1.8
3 h 4.1 ± 0,85 83.5 ± 4.03 1.1 ± 0.21 21.6 ± 1.75
6 h 5.1 ± 0.78 110.6 ± 14.64 2.2 ± 0.57 22.7 ± 0.8
24 h 9.3 ± 0.92 103.8 ± 12.09 7.2 ± 1.56 69.8 ± 4.2
48 h 19.9 ± 2.12 101.9 ± 13.79 20.1 ± 2.05 62.9 ± 3.6
72 h 14.4 ± 0.14 105.1 ± 15.20 18.1 ± 0.64 57.7 ± 8.2
B
Times IL-1 α (pg/ml)a IL- 6 (pg/ml)a TNF-α (pg/ml)a IL-17 (pg/ml)a
30 m 26.5 ± 1.13 126.1 ± 4.17 28.0 ± 2.55 0
1 h 27.5 ± 0.71 118.9 ± 2.26 24.4 ± 0.64 0
6 h 25.7 ± 0.49 112.6 ± 5.23 29.3 ± 1.48 0
24 h 58.3 ± 5.37 111.4 ± 2.76 37.8 ± 0.78 26.8 ± 1.35
48 h 23.1 ± 1.98 113.7 ± 2.90 21.0 ± 0.99 49.8 ± 2.8
72 h 23.5 ± 1.63 114.1 ± 2.97 18.5 ± 1.41 45.7 ± 3.1
amedian value ± standard deviation
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CD4 + cells, and at 40 μg/ml in MT-2 cells (data not
shown). In any case the IC50 value is comparable both
in MT-2 cells and HTLV-1 infected CD4 + .
The recovering from the inhibitory effect of RES
(20 μg/ml) on IL-17 production was evaluated in super-
natants of MT-2 cells at 3 h, 6 h, 24 h and 48 h of cul-
ture, after RES removal. The IL-17 production was still
significantly lower in treated cell cultures than in con-
trols (P < 0.01) and this inhibitory effect lasted at least
48 h (Fig. 3).
Effect of RES on the expression of IL-17 mRNA
The effect of RES was evaluated on IL-17 mRNA using
RT-PCR analysis. Results from a representative experi-
ment are shown in Fig. 2 Panel b. RES at concentration
of 20 μg/ml was clearly capable to down-regulate in 48 h
the IL-17 mRNA in MT-2 cells and in HTLV-1 infected
CD4+ lymphocytes. Accordingly with data showing the
inhibition of IL-17 cytokine production (Fig. 2 Panel a),
this result suggested that RES was most likely able to
interfere with IL-17 release also at transcriptional level.
Effects of RES on NF-kB activity in MT-2 cells
With the aim of better understanding the mechanism
responsible for the inhibitory effect of RES on IL-17 as
well as its effect on the other cytokines assessed, we
verified whether RES might directly affect the activation
of the NF-kB complex. To this end, HTLV-1 chronically
infected MT-2 cells were either treated with 20 μg/ml or
40 μg/ml of RES or exposed to vehicle (as negative con-
trol) and NF-kB activation was assessed as DNA-binding
activity in nuclear lysates, harvested after 1 and 24 h
from RES treatment, respectively, using a non-
radioactive EMSA (Fig. 4). Equal amounts of nuclear ex-
tracts derived from equal amounts of viable cells from
control or RES treated samples, were utilized, in order
to avoid any bias related to differences in total cell num-
ber. A clear dose-dependent inhibition of NF-kB binding
Fig. 1 Inhibitory effect of RES on proinflammatory cytokine production by MT-2 cells. MT-2 cells were treated with 20 μg/ml and 40 μg/ml of RES
for 1 h, 24 h and 48 h and cytokine production was assessed by ELISA. a Effects on IL-1α production. b Effects on IL-6 production. c Effects on
TNF-α production. CTR = cells treated with DMSO alone. Each experiment was performed in quadruplicate. The results are expressed as mean pg/
ml. Error bars are omitted (the standard error SEM were less than 10 %). * P < 0.01
A B
Fig. 2 Inhibitory effect of RES on IL-17 production. PANEL a show the inhibitory effect of different concentrations of RES on IL-17 production. MT-2
cells and HTLV-1 infected CD4+ T cell cultures were treated with RES at 0.612,1.25,2.5,5,10,20 and 40 μg/ml for 48 h of culture. IL-17 production was
assayed by ELISA and the results are expressed as IC50, i.e., the concentration of RES where the IL-17 production is reduced by 50 %. The bars represent
the confidence limits. PANEL b show the Effect of RES on IL-17 transcription in MT-2 cells and HTLV-1 infected CD4+ cells. Cells were treated with RES
at 20 μg/ml for 48 h and IL-17 transcription was assessed by RT-PCR. The image refers to visualization of IL-17 mRNA expression in DMSO treated MT-2
cells, RES-treated MT-2 cells, DMSO treated HTLV-1 infected CD4+ cells and RES-treated HTLV-1 infected CD4+ cells
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activity was found after RES treatment. The suppressive
effect was particularly evident at 40 μg/ml and early after
exposure to the compound (at 1 h after treatment), as
shown by the quantitative determination of the density
of the bands (Fig. 4). Conversely RES at the concentra-
tion of 20 and 40 μg/ml, did not induce downregulation
of HTLV-1 Tax/Rex expression (see Fig. 5).
Discussion
In the present study we investigated the effects of RES
on proinflammatory cytokines production from MT-2
cell line and from peripheral healthy donors CD4+ lym-
phocytes infected in vitro by HTLV-1. HTLV-1 infection
is associated with systemic immune–mediated inflam-
matory diseases whose hallmarks include increased
levels of IFN-γ, TNF-α, and IL-6 [2, 11, 25] and remark-
able tissue damage [1]. The increased production of
proinflammatory cytokines and the expansion of auto-
reactive T cells observed in HTLV-1–infected patients
appear, at least in part, due to the lack of regulatory T
cell function and a decreased ability of IL-10 and TGFβ
to regulate the immune response [26]. In fact, IL-17
mRNA is highly expressed in HTLV-1-infected cells
[13]. In infected CD4+ T cells, the Tax viral protein is
capable of up-regulating the expression of IL-17, which,
in turn, has the ability to stimulate the production of
other inflammatory cytokines and chemokines, including
IL-6, IL-8, GM-CSF and MCP-1 [26]. In previous studies
we found that RES is able to counteract the production
of IL-17 and Th1/Th2 cytokines in an inflammatory cell
model in vitro [17, 18]. Due to these anti-inflammatory
and immunomodulating properties [27]. RES might rep-
resent a good candidate for chemoprevention strategies
or for use in combination therapy in HTLV-1 related
diseases.
In the present study we firstly analyzed the profiles of
inflammatory cytokine production in vitro in two differ-
ent cell systems, including the HTLV-1 transformed
continuous MT-2 cell line and short term culture of
CD4+ lymphocytes from healthy donors immortalized in
our laboratory by HTLV-1.
We showed that HTLV-1 infected cells produce high
amounts of inflammatory cytokines (Table 1), such as
IL-1α, IL-6 and TNF-α, and that RES exerts an inhibi-
tory effects on the HTLV-1 induced production of these
cytokines (Fig. 4). In particular, TNF-α was strongly
inhibited. Further experiments confirmed that RES can
inhibit TNF-α and IFN-γ in vitro even at very low con-
centrations (about 1 μg RES/ml and 5 μg/ml RES re-
spectively, data not shown). The exact role of an
individual cytokine in the complex inflammatory milieu
induced by HTLV-1 infection cannot be easily defined. It
is well known that both TNF − α and IFN-γ exert a syn-
ergistic effect on IL-17-induced production of IL-6 [28].
Fig. 3 Reversibility of the inhibitory effect of RES on IL-17 production
by MT-2 cells. MT-2 cells were treated with 20 μg/ml of RES for 48 h.
IL-17 production has been assessed by ELISA in the supernatants at
3 h, 6 h, 24 h and 48 h of culture after RES removal. CTR = cells treated
with DMSO alone. Each experiment was performed in quadruplicate.
The results are expressed as mean pg/ml. Error bars are omitted (the
standard error SEM were less than 10 %). * P < 0.01
Fig. 4 Suppressive effect of RES on NF-kB activation in MT-2 cells.
MT-2 cells were either treated with vehicle or treated with 20 μg/ml
or 40 μg/ml RES and after 1 h and 24 h, NF-kB complex activation
was assayed by non-radioactive EMSA. The upper panel refers to the
autoradiography film while the lower panels represent the relative
density of the bands with respect to vehicle treated samples, from one
representative experiments of the two performed with similar results
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IL-17 appears to play a key role in the cytokine circuitry
induced by HTLV-1 infection, as shown in HAM/TSP
patients [29]. However, conflicting results have been re-
cently shown on the possible role of Th17 T cells and
IL-17 production in HTLV-1 infected patients [30].
Our results showed that both HTLV-1 infected cell
models spontaneously produce IL-17 in vitro although
with different kinetics. In the MT-2 cell line the release
of IL-17 was detected as early as 30 min, whereas in
HTLV-1 infected CD4+ T cells it was found after 12 h of
culture (Fig. 1). Both cell types reached peak levels of IL-
17 production after 24 or 48 h in culture, respectively.
These data are consistent with previous observations in
HTLV-1-infected T cells showing that IL-17 mRNA is
induced in association with Tax expression [13].
With the aim of investigating the effect of RES, IL-17
production was assessed in MT-2 and in HTLV-1 in-
fected CD4+ T cells in the presence or in the absence of
RES and found that in the presence of RES IL-17 is
strongly reduced reaching a 100 % inhibition both in
MT-2 cells treated with RES 40 μg/ml (Fig. 2 Panel a)
and in CD4+ infected T cells, treated with 20 and 40 μg/
ml of RES (Fig. 2 Panel b), respectively. In order to ex-
clude that the low levels of cytokines might depend on
cytotoxic effects of RES, although in our experimental
conditions the concentrations of RES were well below
the toxic concentrations cell viability was assessed after
RES incubation by Trypan blue exclusion test (data not
shown).
Figure 3 shows that the inhibitory effect of RES on IL-
17 production in MT-2 cells was still present up to 48 h
after its removal at both protein and RNA levels (Fig. 5)
in both cell models. Thus, these data indicate that the
inhibitory effect of RES on IL-17 involve, at least in part,
biochemical pathways independent from those governing
the cell viability.
Molecular pathways presumably involved in the tran-
scriptional activation of the IL-17 gene in HTLV-1-
infected cells include the Tax protein, which in turn
depend on the CREB/ATF pathway and the interferon
regulatory factor 4 (IRF4), a transcription factor that reg-
ulates IL-17 and IL-9, which is over-expressed in HTLV-
1-infected cells with a Th17 phenotype [13]. Moreover, a
key role for the retinoic orphan receptor RORC, a Th17
transcription factor, has been also suggested in the regu-
lation of IL-17 expression [13, 30]. The effect of RES on
the above described molecular pathways is currently un-
known and further studies are needed to understand this
aspect. On the other hand, IL-17 receptor signaling in-
duces the activation of NF-kB, which, in turn, results in
elevated levels of inflammatory cytokines [31].
Recent studies suggest that NF-kB may play a key role
in mediating RES effects since RES-induced inhibition of
inflammatory cytokine production is achieved by sup-
pressing NF-kB activation [32], although it has been ar-
gued that RES might hit multiple targets [33].
In the present study, we found that RES down-
regulate IL-17 in MT-2 cells through an inhibition of
NF-kB activation (Fig. 4). Although it is not possible, at
the moment, to trace the cascade of events triggered by
RES and leading to the down-regulation of IL-17 and
other inflammatory cytokines in HTLV-1 infected cells,
nevertheless, based on our results and on existing litera-
ture [34-36], it appears conceivable that a strict connec-
tion exists between RES-induced inhibition of the
inflammatory cytokine circuitry and the down regulation
of NF-kB.
In addition, it is well recognized that the HTLV-1 Tax
protein primarily targets the IkB kinase complex, result-
ing in persistent activation of NF-kB and upregulation of
its responsive genes that, in turn, are crucial for T cell
survival and cell cycle progression [34]. It has been
Fig. 5 Effect of RES on HTLV-1 Tax/Rex expression. MT-2 cells were either treated with vehicle (CTR) or with 20 μg/ml or 40 μg/ml RES and after
24 h Tax/Rex expression was evaluated through real-time PCR (RQ.PCR). The values were expressed as TaxRex relative mRNA levels in treated cells
with respect to vehicle treated samples
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shown that RES inhibits NF-kB and modulates IkB kin-
ase and this may contribute to the inhibition of inflam-
matory cytokines [35, 36]. Thus, compelling evidence
suggest that the inhibition of NF-kB by RES represents a
key step for the downregulation of inflammatory cyto-
kines. However, whether this depend or not on IL-17, is
still an open question.
On the other hand, the failure of RES in suppressing
IL-6 production could be due to the fact that in addition
to NF-kB mediated transcription, the IL-6 gene can be
activated by alternative mechanisms [37].
RES has been shown to inhibit the replication of her-
pes viruses as well as the growth of EBV-immortalized
cell lines and polyomavirus [38, 39]. In HTLV-1 infec-
tion, RES has been shown to inhibit the growth of virus-
infected cell lines by down-regulating survivin expres-
sion [40]. In our study the treatment of MT-2 cells with
RES was unable to affect HTLV-1 expression. Similarly
Tang et al. [41] have shown that low Res concentrations
did not significantly inhibited virus expression in MT-2
cells in vitro. Conversely they reported that increasing
amount of Res inhibited Tax-mediated LTR transactiva-
tion in SIRT-1 overexpressing HEK293 cells (Tang
et al.). These studies suggest that Res is able to abrogate
Tax transactivation only under condition of LTR overex-
pression, in presence of SIRT-1 deacetylase, while in
physiological conditions the inhibitory effect of Res on
HTLV-1 expression is rather cell type dependent [41].
More recently, it has been shown that RES at high
concentration (50–100 μM) had potent antiproliferative
effect on ATL cells [42].
In our study we found that that although RES did not
inhibit HTLV-1 expression (data not shown), and be-
side an anti-proliferative effect toward HTLV-I infected
cells exerted at high concentrations, at lower concen-
trations RES can exert an evident, dose-dependent anti-
inflammatory activity. These results strongly suggest
RES can either act on cell growth and the inflammatory
circuitries through distinct mechanisms.
Conclusions
Anti-retroviral agents used for HIV have partially im-
proved the prognosis of ATL, but little effect has been
shown on HAM/TSP [43]. Moreover, an effective therapy
for HTLV-1 associated diseases still represent an unmet
need. Results of the present study suggest that RES can
exert an anti-inflammatory activity on HTLV-1 infected
cells at low doses, in association with a suppressive effect
on NF-kB activation. Taken together, these results suggest
that RES, or its derivative, given also its safety profile in
clinical trials [44, 45], might represent a promising thera-
peutic agent, in combination with both anti-inflammatory
and/or antiretroviral drugs, for the treatment of HTLV-1-
related diseases, including HAM/TSP.
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